Controlled Substances: 2014 Proposed Aggregate Production Quota for Four Temporarily Controlled Synthetic Cannabinoids, 13076-13077 [2014-05024]

Download as PDF mstockstill on DSK4VPTVN1PROD with NOTICES 13076 Federal Register / Vol. 79, No. 45 / Friday, March 7, 2014 / Notices remedial orders are used in the United States; (ii) identify any public health, safety, or welfare concerns in the United States relating to the requested remedial orders; (iii) identify like or directly competitive articles that complainant, its licensees, or third parties make in the United States which could replace the subject articles if they were to be excluded; (iv) indicate whether complainant, complainant’s licensees, and/or third party suppliers have the capacity to replace the volume of articles potentially subject to the requested exclusion order and/or a cease and desist order within a commercially reasonable time; and (v) explain how the requested remedial orders would impact United States consumers. Written submissions must be filed no later than by close of business, eight calendar days after the date of publication of this notice in the Federal Register. There will be further opportunities for comment on the public interest after the issuance of any final initial determination in this investigation. Persons filing written submissions must file the original document electronically on or before the deadlines stated above and submit 8 true paper copies to the Office of the Secretary by noon the next day pursuant to section 210.4(f) of the Commission’s Rules of Practice and Procedure (19 CFR 210.4(f)). Submissions should refer to the docket number (‘‘Docket No. 3003’’) in a prominent place on the cover page and/or the first page. (See Handbook for Electronic Filing Procedures, Electronic Filing Procedures 4). Persons with questions regarding filing should contact the Secretary (202–205–2000). Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.5 4 Handbook for Electronic Filing Procedures: https://www.usitc.gov/secretary/fed_reg_notices/ rules/handbook_on_electronic_filing.pdf 5 Electronic Document Information System (EDIS): https://edis.usitc.gov. VerDate Mar<15>2010 18:39 Mar 06, 2014 Jkt 232001 This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of sections 201.10 and 210.8(c) of the Commission’s Rules of Practice and Procedure (19 CFR 201.10, 210.8(c)). By order of the Commission. Issued: February 28, 2014. William R. Bishop, Supervisory Hearings and Information Officer. [FR Doc. 2014–04945 Filed 3–6–14; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [DEA #390P] Controlled Substances: 2014 Proposed Aggregate Production Quota for Four Temporarily Controlled Synthetic Cannabinoids Drug Enforcement Administration (DEA), Department of Justice. ACTION: Notice of a proposed 2014 aggregate production quota for four synthetic cannabinoids. AGENCY: Four synthetic cannabinoids: quinolin-8-yl 1-pentyl-1H-indole-3carboxylate (PB-22; QUPIC); quinolin-8yl 1-(5-fluoropentyl)-1H-indole-3carboxylate (5-fluoro-PB-22; 5F-PB-22); N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(4-fluorobenzyl)-1H-indazole-3carboxamide (AB-FUBINACA); and N(1-amino-3,3-dimethyl-1-oxobutan-2-yl)1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) were temporarily placed in schedule I of the Controlled Substances Act (CSA) by a final order published by the DEA on February 10, 2014 (79 FR 7577). This means that any manufacturer that wishes to manufacture PB-22, 5F-PB-22, ABFUBINACA, or ADB-PINACA after February 10, 2014, must be registered with the DEA and have obtained a manufacturing quota for PB-22, 5F-PB22, AB-FUBINACA, or ADB-PINACA pursuant to 21 CFR part 1303. The DEA cannot issue individual manufacturing quotas for PB–22, 5F– PB–22, AB–FUBINACA, or ADB– PINACA unless and until it establishes an aggregate production quota. Therefore, this notice proposes a 2014 aggregate production quota for PB–22, 5F–PB–22, AB–FUBINACA, and ADB– PINACA. DATES: Comments or objections should be received on or before April 7, 2014. ADDRESSES: To ensure proper handling of comments, please reference ‘‘Docket SUMMARY: PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 No. DEA–390P’’ on all electronic and written correspondence. The DEA encourages that all comments be submitted electronically through www.regulations.gov using the electronic comment form provided on that site. An electronic copy of this document is also available at www.regulations.gov for easy reference. Paper comments that duplicate the electronic submission are not necessary as all comments submitted to www.regulations.gov will be posted for public review and are part of the official docket record. Written comments submitted via regular or express mail should be sent to the Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: (202) 598–6812. SUPPLEMENTARY INFORMATION: Posting of Public Comments The Freedom of Information Act applies to all comments received. All comments received are considered part of the public record and made available for public inspection online at www.regulations.gov and in the DEA’s public docket. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase ‘‘PERSONAL IDENTIFYING INFORMATION’’ in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted. If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase ‘‘CONFIDENTIAL BUSINESS INFORMATION’’ in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. If a comment has so much confidential business information that it cannot be effectively E:\FR\FM\07MRN1.SGM 07MRN1 Federal Register / Vol. 79, No. 45 / Friday, March 7, 2014 / Notices redacted, all or part of that comment may not be posted online or made available in the public docket. Personal identifying information and confidential business information identified and located as set forth above will be redacted, and the comment, in redacted form, will be posted online and placed in the DEA’s public docket file. If you wish to inspect the DEA’s public docket file in person by appointment, please see the FOR FURTHER INFORMATION CONTACT mstockstill on DSK4VPTVN1PROD with NOTICES paragraph. Background Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II each year. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104. The DEA established the 2014 aggregate production quotas for substances in schedules I and II on September 9, 2013 (78 FR 55099). Subsequently, on January 10, 2014, the DEA published in the Federal Register a notice of intent to temporarily place four synthetic cannabinoids: quinolin-8yl 1-pentyl-1H-indole-3-carboxylate (PB22; QUPIC); quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22); N-(1-amino3-methyl-1-oxobutan-2-yl)-1-(4fluorobenzyl)-1H-indazole-3carboxamide (AB-FUBINACA); and N(1-amino-3,3-dimethyl-1-oxobutan-2-yl)1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) in schedule I of the CSA (79 FR 1776). On February 10, 2014, the DEA published in the Federal Register a final order to temporarily place these four synthetic cannabinoids in schedule I of the CSA (79 FR 7577), making all regulations pertaining to schedule I controlled substances applicable to the manufacture of these four synthetic cannabinoids, including the establishment of an aggregate production quota pursuant to 21 CFR 1303.11. PB-22, 5F-PB-22, AB-FUBINACA, and ADB-PINACA were non-controlled substances when the aggregate production quotas for schedule I and II substances were established, therefore, no aggregate production quotas for PB22, 5F-PB-22, AB-FUBINACA, and ADBPINACA were established at that time. In determining the 2014 aggregate production quotas of these four cannabinoids, the Deputy Administrator VerDate Mar<15>2010 18:39 Mar 06, 2014 Jkt 232001 considered the following factors in accordance with 21 U.S.C. 826(a) and 21 CFR 1303.11: (1) Total estimated net disposal of each substance by all manufacturers; (2) estimated trends in the national rate of net disposal; (3) total estimated inventories of the basic class and of all substances manufactured from the class; (4) projected demand for each class as indicated by procurement quotas requested pursuant to 21 CFR 1303.12; and (5) other factors affecting medical, scientific, research, and industrial needs of the United States and lawful export requirements, as the Deputy Administrator finds relevant. These quotas do not include imports of controlled substances for use in industrial processes. The Deputy Administrator, therefore, proposes that the year 2014 aggregate production quotas for the following temporarily controlled schedule I controlled substances, expressed in grams of anhydrous acid or base, be established as follows: 13077 Dated: February 28, 2014. Thomas M. Harrigan, Deputy Administrator. [FR Doc. 2014–05024 Filed 3–6–14; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Office of Justice Programs [OJP (BJA) Docket No. 1648] Meeting of the Department of Justice’s (DOJ’s) National Motor Vehicle Title Information System (NMVTIS) Federal Advisory Committee Office of Justice Programs (OJP), Justice. ACTION: Notice of meeting. AGENCY: This is an announcement of a webinar meeting of DOJ’s National Motor Vehicle Title Information System (NMVTIS) Federal Advisory Committee to discuss various issues relating to the operation and implementation of NMVTIS. SUMMARY: The meeting will take place on Wednesday March 26, 2014, from 1:00 p.m. to 3:00 p.m. ET. ADDRESSES: This will be a webinar N-(1-amino-3,3-dimethyl-1meeting. Those wishing to participate oxobutan-2-yl)-1-pentylare asked to email their request to the 1H-indazole-3Designated Federal Employee (DFE) carboxamide (ADB– PINACA) ............................ 15 g listed below. N-(1-amino-3-methyl-1FOR FURTHER INFORMATION CONTACT: oxobutan-2-yl)-1-(4Todd Brighton, Designated Federal fluorobenzyl)-1H-indazoleEmployee (DFE), Bureau of Justice 3-carboxamide (AB– FUBINACA) ....................... 15 g Assistance, Office of Justice Programs, 810 7th Street NW., Washington, DC quinolin-8-yl 1-(520531; Phone: (202) 616–3879 [note: fluoropentyl)-1H-indole-3carboxylate (5-fluoro-PB– this is not a toll-free number]; Email: 22; 5F–PB–22) .................. 15 g Todd.Brighton@usdoj.gov quinolin-8-yl 1-pentyl-1HSUPPLEMENTARY INFORMATION: This indole-3-carboxylate (PB– 22; QUPIC) ....................... 15 g meeting is open to the public. Members of the public who wish to participate in the webinar must register with Mr. Comments Brighton at the above address at least Pursuant to 21 CFR 1303.11, any seven (7) days in advance of the interested person may submit written meeting. Registrations will be accepted comments on or objections to these on a space available basis. Access to the proposed determinations. Based on meeting will not be allowed without comments received in response to this registration. Interested persons whose notice, the Deputy Administrator may registrations have been accepted may be hold a public hearing on one or more permitted to participate in the issues raised. In the event the Deputy discussions at the discretion of the Administrator decides in his sole meeting chairman and with approval of discretion to hold such a hearing, the the DFE. Deputy Administrator will publish a Anyone requiring special notice of any such hearing in the accommodations should notify Mr. Federal Register. After consideration of Brighton at least seven (7) days in any comments and after a hearing, if one advance of the meeting. is held, the Deputy Administrator will Purpose publish in the Federal Register a final order establishing the 2014 aggregate The NMVTIS Federal Advisory production quota for PB–22, 5F–PB–22, Committee will provide input and AB–FUBINACA, and ADB–PINACA. recommendations to the Office of Justice PO 00000 DATES: Basic class—Schedule I Frm 00043 Fmt 4703 Sfmt 4703 Proposed 2014 quota E:\FR\FM\07MRN1.SGM 07MRN1

Agencies

[Federal Register Volume 79, Number 45 (Friday, March 7, 2014)]
[Notices]
[Pages 13076-13077]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05024]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA 390P]


Controlled Substances: 2014 Proposed Aggregate Production Quota 
for Four Temporarily Controlled Synthetic Cannabinoids

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Notice of a proposed 2014 aggregate production quota for four 
synthetic cannabinoids.

-----------------------------------------------------------------------

SUMMARY: Four synthetic cannabinoids: quinolin-8-yl 1-pentyl-1H-indole-
3-carboxylate (PB-22; QUPIC); quinolin-8-yl 1-(5-fluoropentyl)-1H-
indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22); N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-
FUBINACA); and N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
indazole-3-carboxamide (ADB-PINACA) were temporarily placed in schedule 
I of the Controlled Substances Act (CSA) by a final order published by 
the DEA on February 10, 2014 (79 FR 7577). This means that any 
manufacturer that wishes to manufacture PB-22, 5F-PB-22, AB-FUBINACA, 
or ADB-PINACA after February 10, 2014, must be registered with the DEA 
and have obtained a manufacturing quota for PB-22, 5F-PB-22, AB-
FUBINACA, or ADB-PINACA pursuant to 21 CFR part 1303.
    The DEA cannot issue individual manufacturing quotas for PB-22, 5F-
PB-22, AB-FUBINACA, or ADB-PINACA unless and until it establishes an 
aggregate production quota. Therefore, this notice proposes a 2014 
aggregate production quota for PB-22, 5F-PB-22, AB-FUBINACA, and ADB-
PINACA.

DATES: Comments or objections should be received on or before April 7, 
2014.

ADDRESSES: To ensure proper handling of comments, please reference 
``Docket No. DEA-390P'' on all electronic and written correspondence. 
The DEA encourages that all comments be submitted electronically 
through www.regulations.gov using the electronic comment form provided 
on that site. An electronic copy of this document is also available at 
www.regulations.gov for easy reference. Paper comments that duplicate 
the electronic submission are not necessary as all comments submitted 
to www.regulations.gov will be posted for public review and are part of 
the official docket record. Written comments submitted via regular or 
express mail should be sent to the Drug Enforcement Administration, 
Attention: DEA Federal Register Representative/ODW, 8701 Morrissette 
Drive, Springfield, Virginia 22152.

FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Office of Diversion 
Control, Drug Enforcement Administration; Mailing Address: 8701 
Morrissette Drive, Springfield, Virginia 22152, Telephone: (202) 598-
6812.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

    The Freedom of Information Act applies to all comments received. 
All comments received are considered part of the public record and made 
available for public inspection online at www.regulations.gov and in 
the DEA's public docket. Such information includes personal identifying 
information (such as your name, address, etc.) voluntarily submitted by 
the commenter.
    If you want to submit personal identifying information (such as 
your name, address, etc.) as part of your comment, but do not want it 
to be posted online or made available in the public docket, you must 
include the phrase ``PERSONAL IDENTIFYING INFORMATION'' in the first 
paragraph of your comment. You must also place all the personal 
identifying information you do not want posted online or made available 
in the public docket in the first paragraph of your comment and 
identify what information you want redacted.
    If you want to submit confidential business information as part of 
your comment, but do not want it to be posted online or made available 
in the public docket, you must include the phrase ``CONFIDENTIAL 
BUSINESS INFORMATION'' in the first paragraph of your comment. You must 
also prominently identify confidential business information to be 
redacted within the comment. If a comment has so much confidential 
business information that it cannot be effectively

[[Page 13077]]

redacted, all or part of that comment may not be posted online or made 
available in the public docket.
    Personal identifying information and confidential business 
information identified and located as set forth above will be redacted, 
and the comment, in redacted form, will be posted online and placed in 
the DEA's public docket file.
    If you wish to inspect the DEA's public docket file in person by 
appointment, please see the For Further Information Contact paragraph.

Background

    Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney 
General establish aggregate production quotas for each basic class of 
controlled substance listed in schedules I and II each year. This 
responsibility has been delegated to the Administrator of the DEA by 28 
CFR 0.100. The Administrator, in turn, has redelegated this function to 
the Deputy Administrator, pursuant to 28 CFR 0.104.
    The DEA established the 2014 aggregate production quotas for 
substances in schedules I and II on September 9, 2013 (78 FR 55099). 
Subsequently, on January 10, 2014, the DEA published in the Federal 
Register a notice of intent to temporarily place four synthetic 
cannabinoids: quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; 
QUPIC); quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-
fluoro-PB-22; 5F-PB-22); N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA); and N-(1-amino-
3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-
PINACA) in schedule I of the CSA (79 FR 1776). On February 10, 2014, 
the DEA published in the Federal Register a final order to temporarily 
place these four synthetic cannabinoids in schedule I of the CSA (79 FR 
7577), making all regulations pertaining to schedule I controlled 
substances applicable to the manufacture of these four synthetic 
cannabinoids, including the establishment of an aggregate production 
quota pursuant to 21 CFR 1303.11.
    PB-22, 5F-PB-22, AB-FUBINACA, and ADB-PINACA were non-controlled 
substances when the aggregate production quotas for schedule I and II 
substances were established, therefore, no aggregate production quotas 
for PB-22, 5F-PB-22, AB-FUBINACA, and ADB-PINACA were established at 
that time.
    In determining the 2014 aggregate production quotas of these four 
cannabinoids, the Deputy Administrator considered the following factors 
in accordance with 21 U.S.C. 826(a) and 21 CFR 1303.11: (1) Total 
estimated net disposal of each substance by all manufacturers; (2) 
estimated trends in the national rate of net disposal; (3) total 
estimated inventories of the basic class and of all substances 
manufactured from the class; (4) projected demand for each class as 
indicated by procurement quotas requested pursuant to 21 CFR 1303.12; 
and (5) other factors affecting medical, scientific, research, and 
industrial needs of the United States and lawful export requirements, 
as the Deputy Administrator finds relevant. These quotas do not include 
imports of controlled substances for use in industrial processes.
    The Deputy Administrator, therefore, proposes that the year 2014 
aggregate production quotas for the following temporarily controlled 
schedule I controlled substances, expressed in grams of anhydrous acid 
or base, be established as follows:

 
------------------------------------------------------------------------
                                                           Proposed 2014
                 Basic class--Schedule I                       quota
------------------------------------------------------------------------
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-               15 g
 indazole-3-carboxamide (ADB-PINACA)....................
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-            15 g
 1H-indazole-3-carboxamide (AB-FUBINACA)................
quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate            15 g
 (5-fluoro-PB-22; 5F-PB-22).............................
quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22;              15 g
 QUPIC).................................................
------------------------------------------------------------------------

Comments

    Pursuant to 21 CFR 1303.11, any interested person may submit 
written comments on or objections to these proposed determinations. 
Based on comments received in response to this notice, the Deputy 
Administrator may hold a public hearing on one or more issues raised. 
In the event the Deputy Administrator decides in his sole discretion to 
hold such a hearing, the Deputy Administrator will publish a notice of 
any such hearing in the Federal Register. After consideration of any 
comments and after a hearing, if one is held, the Deputy Administrator 
will publish in the Federal Register a final order establishing the 
2014 aggregate production quota for PB-22, 5F-PB-22, AB-FUBINACA, and 
ADB-PINACA.

    Dated: February 28, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014-05024 Filed 3-6-14; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.